Aditxt (NASDAQ: ADTX), a company dedicated to discovering, developing and deploying promising health innovations, entered into a definitive agreement with Evofem Biosciences Inc. (OTCQB: EVFM) late last year, and Evofem is reporting its preliminary financial results for 2023, which include record net sales of Phexxi(R), its hormone-free contraceptive gel. According to the report, Phexxi is seeing a third consecutive year of net sales growth; the report also indicated that the company has reduced its total operating expenses by more than 60%. Evofem, a commercial stage women’s health innovator, and Aditxt announced the planned acquisition in December 2023, which Evofem believes is a compelling opportunity to accelerate its growth trajectory; the companies are eyeing a mid-2024 close. “Strong consumer demand for Phexxi and the expansion of coverage and reimbursement enabled us to achieve our third consecutive year of revenue growth,” said Evofem Biosciences CEO Saundra Pelletier in the press release. “We delivered more than $18 million in net sales for 2023 despite ongoing austerity measures that whittled our sales force down to just 16 and permitted no investment in growing the brand. Our growth testifies to the strength and persistence of Evofem’s current team as well as the loyal users and prescribers of Phexxi nationwide.”
To view the full press release, visit https://ibn.fm/9eQy5
About Aditxt Inc.
Aditxt is focused on discovering, developing and deploying promising health innovations. Aditxt’s diverse portfolio includes Adimune(TM) Inc., developing a new class of therapeutics designed to retrain the immune system to address organ rejection, autoimmunity and allergies; Adivir(TM) Inc., focused on identifying, developing and commercializing new ways to treat infectious diseases; and Pearsanta(TM) Inc., offering timely, convenient and high-quality personalized lab testing anytime and anywhere, backed by its CLIA-certified and CAP-accredited monitoring center. For more information, please visit www.Aditxt.com.
NOTE TO INVESTORS: The latest news and updates relating to ADTX are available in the company’s newsroom at https://ibn.fm/ADTX
InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.
For more information, please visit https://www.InvestorWire.com
InvestorWire is powered by IBN